What to Expect at the World’s Only RNA-Targeted Small Molecule Forum in 2025
Step into the future of RNA-targeted drugs at the 8th RNA-Targeted Drug Discovery & Development Summit. With 75% new speakers from 2024 and 50% of the speakers sharing new data, this summit is set to offer the latest data and fresh insights on small molecules targeting RNA.
This year, join 80+ experts in RNA biology, drug discovery, medicinal chemistry and structural biology to gain the latest data on visualizing dynamic RNA structures, identifying functional binders, improving selectivity, enhancing delivery stability and achieving oral bioavailability.
Whether you're focused on RNA splice modulators, covalent binders, proximity inducing drugs, or direct RNA binders this event will give you the tools and insights to fast track the discovery of functional binders and accelerate your pipeline of RNA-targeted small molecules to the clinic.
Join us in December to connect with your global community at the world’s only meeting for RNA-targeted drug experts.
Is This the Right Summit for You? Here's How to Decide:
Are you seeking to connect with pioneering senior leaders, cutting-edge researchers, and key opinion leaders (KOLs) in the RNA-targeted drug discovery field, including CXOs, Directors, and Scientists driving RNA biology, chemistry, structural science and translational research in biopharma?
Join this exclusive community over three days to explore the evolving RNA-targeted drug discovery landscape, assess the latest breakthrough technologies in RNA structure visualization, gain hard-won lessons into functional RNA binding, and unlock the full therapeutic potential of RNA with selective splice modulators, direct binders and epitranscriptomic approaches.
Join Your Peers to:
Build faster and more reliable platforms for RNA splice modulators through insights on rapid hit screening and optimizing hit-tolead chemistry with PTC Therapeutics and Rgenta Therapeutics
Progress your RNA splice modulators to the clinic with the latest data on lead compound optimization, clinical readiness and IND-enabling studies from Remix Therapeutics and ReviR Therapeutics
Design RNAtargeted therapeutics for nucleotide repeat disorders with fresh insights on target validation and compoundoptimization against Huntington’s and Myotonic dystrophy type 1 with Arrakis Therapeutics and the CHDI Foundation
Optimize selective and functional RNA binder discovery with high-throughput, structure-driven screening to decode structure-activity relationships with Wayfinder Bio and xFOREST Therapeutics
Unlock novel RNA targets with large scale tertiary structure and FRET-based screens to unveil new ligandable RNA motifs with UNC at Chapel Hill and Yale University
Explore the Full Event Guide
-
- 25+ Expert Speakers
- 3 Days of RNA-Targeted Content
- 2 Interactive Workshops on Functional Binder Discovery
- Investments & Deals Panel
